Results 131 to 140 of about 13,190 (254)

Functional insights into Plasmodium actin-depolymerizing factor interactions with phosphoinositides. [PDF]

J Biol Chem
Lasiwa D, Kursula I.
europepmc   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Physiological roles of phosphoinositides and inositol phosphates: Implications for metabolic dysfunction-associated steatotic liver disease. [PDF]

Clin Sci (Lond)
Cheng Z, Montgomery MK.
europepmc   +1 more source

The selective degradation of PDE4B shortform, using a PROTAC, leads to inhibition of several hallmarks of cancer in HCT116 cells

British Journal of Pharmacology, EarlyView.
Background and Purpose Colorectal cancer is one of the most prevalent cancers worldwide, and novel precision medicine approaches are rapidly improving patient outcomes. Phosphodiesterase 4B (PDE4B) is a member of an enzyme family (PDE4) that hydrolyses intracellular cAMP to control spatial and temporal signalling cues.
Alina Zorn, John Daniel Pediani, Madihah Hussain, Jiayue Ling, Elaine Brown, Igor Belka, Eduardo Torres, Cathy Swindlehurst, Kyle Chan, David Stirling, George S. Baillie, Yuan Yan Sin   +11 more
wiley   +1 more source

Expression and purification of Steroidogenic Factor-1 (NR5A1) nuclear receptor ligand binding domain complexed with the signaling phosphoinositide lipid PI(3,4,5)P₃. [PDF]

Methods Enzymol
Campbell AN, Cutright AJ, Martin J, Kheda A, Loi MNC, Blind RD.   +5 more
europepmc   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

The oily nucleus- role of phospholipids in genome biology: membrane-directed roles and signaling in the nucleoplasm. [PDF]

Cell Mol Life Sci
Umair Z, Nawaz Z, Hasnain S, Fischle W.
europepmc   +1 more source

CD93—An emerging vascular target in cancer therapy

British Journal of Pharmacology, EarlyView.
Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira, Stefano Barbera, Roberta Lugano, Anna Dimberg   +3 more
wiley   +1 more source

Toward a molecular logic of lipid droplet heterogeneity? [PDF]

Proc Natl Acad Sci U S A
Vanni S.
europepmc   +1 more source

Mechanisms of resistance to macrophage checkpoint inhibitors in B‐cell non‐Hodgkin lymphoma

British Journal of Haematology, EarlyView.
Zachary Hunzeker, Francisco Javier de la Rosa, Andrey Tyshevich, Darya Shavronskaya, Julia Alesse, Noel English, Lizzie Sheehan, Nikita Syzrantsev, Alexander Nesmelov, Hans‐Guido Wendel, Paolo Strati   +10 more
wiley   +1 more source